When we excluded the ADAURA trial, although the superiority of first-generation EGFR-TKIs on 2- and 3-year DFS rates remained (RR, 0.69 and 0.81; P < 0.001 and P = 0.001, respectively; Fig. S1), no significant advantage was observed in the 5-year DFS rate for the first-generation EGFR-TKIs in EGFR-mutant NSCLC patients (RR, 0.95; P = 0.886; Fig. 2B). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.